cd4 car-t cell
Cell therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2019 (NCT03829540)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- T-cell surface antigen CD4Immunity, passive
CD4 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06197672 | Phase 1 | Mar 19, 2024 | Indiana University |
| NCT06071624 | Phase 1 | Jan 31, 2024 | iCell Gene Therapeutics, Indiana University, The Leukemia and Lymphoma Society |
| NCT04162340 | Phase 1 | Nov 30, 2019 | iCell Gene Therapeutics, Peking University, People's Liberation Army of China |
| NCT03829540 | Phase 1 | Jun 15, 2019 | iCell Gene Therapeutics, Stony Brook University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| iCell Gene Therapeutics | For profit | 3 | 1 | 1 | 2019 |
| Indiana University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2019 |
| Stony Brook University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2024 |
6 organizations
Page 1 / 1